• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

亨廷顿舞蹈症中强直与舞蹈症的神经化学底物

Neurochemical substrates of rigidity and chorea in Huntington's disease.

作者信息

Storey E, Beal M F

机构信息

Neurochemistry Laboratory, Massachusetts General Hospital, Boston.

出版信息

Brain. 1993 Oct;116 ( Pt 5):1201-22. doi: 10.1093/brain/116.5.1201.

DOI:10.1093/brain/116.5.1201
PMID:7693298
Abstract

Huntington's disease is a progressive degenerative neurological disorder which produces a characteristic movement disorder termed chorea. Although chorea is associated with dysfunction of the basal ganglia, the underlying mechanisms by which dyskinesias such as chorea are produced, are poorly understood. Recent studies in primates have led to experimental models of chorea with postulated involvement of specific neural pathways. In the present study we attempted to determine the validity of the experimental models by measuring concentrations of gamma-aminobutyric acid (GABA), glutamate, substance P and met-enkephalin in the basal ganglia of Huntington's disease patients who manifested either chorea or rigidity/bradykinesia within 6 months of death. We also characterized changes in the Huntington's disease patients according to pathological grade, since this may be a confounding factor. We analysed post-mortem brain tissue from 12 controls, and 11 grade 3 and 12 grade 4 Huntington's disease patients. The grade 3 and 4 cases consisted of eight adult-onset choreic, nine adult-onset rigid and six juvenile-onset rigid patients. We also analysed the putamen and globus pallidus from 11 grade 2 adult onset choreic Huntington's disease patients. A model of chorea based on experimental studies in primates proposes that a loss of striatal GABAergic inhibitory projections to the globus pallidus externa leads to increased activity of the inhibitory globus pallidus externa GABAergic neurons which project to the subthalamic nucleus. It is believed that the loss of GABAergic inputs to the globus pallidus externa precedes a loss of GABAergic input to the globus pallidus interna, which occurs later in the disease and is associated with the development of rigidity and bradykinesia. In the choreic Huntington's disease patients whom we studied, there was a greater loss of GABA in the globus pallidus externa than in the globus pallidus interna, and the globus pallidus interna: globus pallidus externa GABA ratio was significantly increased compared with rigid patients. There were also increases in GABA in the subthalamic nucleus in the choreic patients, although this did not reach significance. A differential loss of met-enkephalin in the globus pallidus externa compared with substance P loss in the globus pallidus interna was not observed in either the choreic patients with advanced disease or the grade II patients. There was a significant increase in GABA concentrations in the ventroanterior nucleus of the thalamus in the choreic patients compared with rigid/bradykinetic patients.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

亨廷顿舞蹈症是一种进行性退行性神经疾病,会导致一种名为舞蹈症的特征性运动障碍。尽管舞蹈症与基底神经节功能障碍有关,但舞蹈症等运动障碍产生的潜在机制仍知之甚少。最近对灵长类动物的研究已得出舞蹈症的实验模型,并推测特定神经通路参与其中。在本研究中,我们试图通过测量在死亡6个月内表现出舞蹈症或强直/运动迟缓的亨廷顿舞蹈症患者基底神经节中γ-氨基丁酸(GABA)、谷氨酸、P物质和甲硫氨酸脑啡肽的浓度,来确定这些实验模型的有效性。我们还根据病理分级对亨廷顿舞蹈症患者的变化进行了特征描述,因为这可能是一个混杂因素。我们分析了12名对照者以及11名3级和12名4级亨廷顿舞蹈症患者的死后脑组织。3级和4级病例包括8名成年发病的舞蹈症患者、9名成年发病的强直患者和6名青少年发病的强直患者。我们还分析了11名2级成年发病舞蹈症型亨廷顿舞蹈症患者的壳核和苍白球。基于对灵长类动物的实验研究建立的舞蹈症模型提出,纹状体向外侧苍白球的GABA能抑制性投射丧失会导致投射到丘脑底核的外侧苍白球GABA能抑制性神经元活性增加。据信,外侧苍白球GABA能输入的丧失先于内侧苍白球GABA能输入的丧失,内侧苍白球GABA能输入的丧失在疾病后期出现,并与强直和运动迟缓的发展有关。在我们研究的舞蹈症型亨廷顿舞蹈症患者中,外侧苍白球中GABA的丧失比内侧苍白球更严重,与强直患者相比,内侧苍白球与外侧苍白球的GABA比值显著增加。舞蹈症患者丘脑底核中的GABA也有所增加,但未达到显著水平。在晚期舞蹈症患者或2级患者中,均未观察到外侧苍白球中甲硫氨酸脑啡肽的丧失与内侧苍白球中P物质丧失的差异。与强直/运动迟缓患者相比,舞蹈症患者丘脑腹前核中的GABA浓度显著增加。(摘要截选至400字)

相似文献

1
Neurochemical substrates of rigidity and chorea in Huntington's disease.亨廷顿舞蹈症中强直与舞蹈症的神经化学底物
Brain. 1993 Oct;116 ( Pt 5):1201-22. doi: 10.1093/brain/116.5.1201.
2
Striatal and nigral neuron subpopulations in rigid Huntington's disease: implications for the functional anatomy of chorea and rigidity-akinesia.僵直型亨廷顿舞蹈病中的纹状体和黑质神经元亚群:对舞蹈症和僵直-运动不能功能解剖学的影响
Ann Neurol. 1990 Apr;27(4):357-65. doi: 10.1002/ana.410270403.
3
The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.亨廷顿舞蹈病中的神经退行性变模式:亨廷顿舞蹈病患者人类基底神经节中大麻素、多巴胺、腺苷和GABA(A)受体改变的比较研究
Neuroscience. 2000;97(3):505-19. doi: 10.1016/s0306-4522(00)00008-7.
4
Pallidal GABA and chorea in Huntington's disease.苍白球γ-氨基丁酸与亨廷顿舞蹈病中的舞蹈症
J Neural Transm Gen Sect. 1990;81(3):241-6. doi: 10.1007/BF01245046.
5
Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis.使用高分辨率图像分析在低度亨廷顿舞蹈病患者的外侧苍白球中脑啡肽免疫反应性优先丧失的证据。
Neuroscience. 1995 Jan;64(2):397-404. doi: 10.1016/0306-4522(94)00427-7.
6
Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease.亨廷顿舞蹈病患者苍白球中大麻素(CB(1))、γ-氨基丁酸A(GABA(A))和γ-氨基丁酸B(GABA(B))受体亚基的变化
J Chem Neuroanat. 2009 Jul;37(4):266-81. doi: 10.1016/j.jchemneu.2009.02.001. Epub 2009 Feb 21.
7
Immunocytochemical studies of substance P and leucine-enkephalin in Huntington's disease.亨廷顿病中P物质和亮氨酸脑啡肽的免疫细胞化学研究。
Brain Res. 1983 Dec 19;289(1-2):11-26. doi: 10.1016/0006-8993(83)90003-3.
8
Studies on neurotransmitter markers and striatal neuronal cell density in Huntington's disease and dentatorubropallidoluysian atrophy.亨廷顿舞蹈病和齿状核红核苍白球路易体萎缩症中神经递质标志物及纹状体神经元细胞密度的研究
J Neurol Sci. 1985 Sep;70(2):151-65. doi: 10.1016/0022-510x(85)90084-x.
9
Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study.亨廷顿舞蹈症及其他舞蹈病患者纹状体D1和D2受体结合情况:一项正电子发射断层扫描研究
Brain. 1995 Jun;118 ( Pt 3):689-96. doi: 10.1093/brain/118.3.689.
10
A detailed examination of substance P in pathologically graded cases of Huntington's disease.对亨廷顿舞蹈病病理分级病例中P物质的详细检查。
J Neurol Sci. 1988 Mar;84(1):51-61. doi: 10.1016/0022-510x(88)90173-6.

引用本文的文献

1
Identification of molecular targets and small drug candidates for Huntington's disease via bioinformatics and a network-based screening approach.通过生物信息学和基于网络的筛选方法鉴定亨廷顿病的分子靶标和小分子药物候选物。
J Cell Mol Med. 2024 Aug;28(16):e18588. doi: 10.1111/jcmm.18588.
2
Salivary Huntingtin protein is uniquely associated with clinical features of Huntington's disease.唾液亨廷顿蛋白与亨廷顿病的临床特征有独特关联。
Sci Rep. 2023 Jan 19;13(1):1034. doi: 10.1038/s41598-023-28019-y.
3
Cortical Control of Subthalamic Neuronal Activity through the Hyperdirect and Indirect Pathways in Monkeys.
猴子中通过直接通路和间接通路的皮层对苍白球神经元活动的控制。
J Neurosci. 2020 Sep 23;40(39):7451-7463. doi: 10.1523/JNEUROSCI.0772-20.2020. Epub 2020 Aug 26.
4
Disrupted striatal neuron inputs and outputs in Huntington's disease.亨廷顿病中纹状体神经元输入和输出的紊乱。
CNS Neurosci Ther. 2018 Apr;24(4):250-280. doi: 10.1111/cns.12844.
5
Alteration of GABAergic neurotransmission in Huntington's disease.亨廷顿病中 GABA 能神经递质的改变。
CNS Neurosci Ther. 2018 Apr;24(4):292-300. doi: 10.1111/cns.12826. Epub 2018 Feb 21.
6
The role of the human globus pallidus in Huntington's disease.人类苍白球在亨廷顿舞蹈病中的作用。
Brain Pathol. 2016 Nov;26(6):741-751. doi: 10.1111/bpa.12429.
7
Genetics and neuropathology of Huntington's disease.亨廷顿病的遗传学和神经病理学。
Int Rev Neurobiol. 2011;98:325-72. doi: 10.1016/B978-0-12-381328-2.00014-6.
8
Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.亨廷顿病中神经元的差异易损性:细胞类型特异性特征的作用。
J Neurochem. 2010 Jun;113(5):1073-91. doi: 10.1111/j.1471-4159.2010.06672.x. Epub 2010 Mar 17.
9
Saccadic impairments in Huntington's disease.亨廷顿舞蹈症中的眼球跳动障碍
Exp Brain Res. 2008 Apr;186(3):457-69. doi: 10.1007/s00221-007-1248-x. Epub 2008 Jan 10.
10
Imaging in cell-based therapy for neurodegenerative diseases.基于细胞疗法治疗神经退行性疾病的影像学研究
Eur J Nucl Med Mol Imaging. 2005 Dec;32 Suppl 2:S417-34. doi: 10.1007/s00259-005-1909-6.